for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Haemonetics Corporation

HAE

Latest Trade

84.50USD

Change

0.00(0.00%)

Volume

222

Today's Range

--

 - 

--

52 Week Range

63.41

 - 

130.91

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
84.50
Open
0.00
Volume
222
3M AVG Volume
14.28
Today's High
--
Today's Low
--
52 Week High
130.91
52 Week Low
63.41
Shares Out (MIL)
50.70
Market Cap (MIL)
4,236.42
Forward P/E
33.94
Dividend (Yield %)
--

Next Event

Q2 2021 Haemonetics Corp Earnings Release

Latest Developments

More

Haemonetics Posts Quarterly Earnings Per Share $0.21

Haemonetics Reports Blood Filter Supply Agreement, Sale Of Puerto Rico-Based Operations To GVS

GPI SpA To Acquire Haemonetics’ U.S. Blood Donor Software Assets

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Haemonetics Corporation

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company's segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals. The Company enables plasma collection customers to source from it a range of products necessary for plasma collection and storage, including PCS brand plasma collection equipment and disposables, plasma collection containers and intravenous solutions, such as saline. Haemonetics offers automated blood component and manual whole blood collection systems to blood collection centers to collect blood products. The Company offers a range of blood management solutions. The Company has a suite of integrated software solutions, which include solutions for blood drive planning and blood collection.

Industry

Medical Equipment & Supplies

Contact Info

125 SUMMER STREET

BOSTON, MA

02110

United States

+1.781.8487100

https://www.haemonetics.com

Executive Leadership

Richard J. Meelia

Independent Chairman of the Board

Christopher A. Simon

President, Chief Executive Officer, Director

William P. Burke

Chief Financial Officer, Executive Vice President

Anila Lingamneni

Executive Vice President, Chief Technology Officer

Michelle L. Basil

Executive Vice President, General Counsel

Key Stats

2.00 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.9K

2019

1.0K

2020

1.0K

2021(E)

0.9K
EPS (USD)

2018

1.870

2019

2.390

2020

3.310

2021(E)

2.462
Price To Earnings (TTM)
45.21
Price To Sales (TTM)
4.48
Price To Book (MRQ)
6.96
Price To Cash Flow (TTM)
21.28
Total Debt To Equity (MRQ)
86.80
LT Debt To Equity (MRQ)
48.79
Return on Investment (TTM)
9.59
Return on Equity (TTM)
7.10

Latest News

Latest News

BRIEF-Haemonetics CEO Christopher Simon's 2020 Total Compensation Was $9.4 Mln Vls $8.6 Million In 2019

* HAEMONETICS SAYS CEO CHRISTOPHER A. SIMON’S FY 2020 TOTAL COMPENSATION WAS $9.4 MILLION VERSUS $8.6 MILLION IN FY 2019 - SEC FILING

BRIEF-Haemonetics Reports Blood Filter Supply Agreement, Sale Of Puerto Rico-Based Operations To GVS

* HAEMONETICS ANNOUNCES BLOOD FILTER SUPPLY AGREEMENT AND SALE OF PUERTO RICO-BASED MANUFACTURING OPERATIONS TO GVS, S.P.A

BRIEF-Haemonetics Says GPI Will Pay Co $14 Mln In Upfront Cash At Closing Of Asset Transfer

* HAEMONETICS - UNDER TERMS OF ASSET PURCHASE AGREEMENT WITH GPI GROUP, GPI WILL PAY CO $14 MILLION IN UPFRONT CASH AT CLOSING OF ASSET TRANSFER Source: (https://bit.ly/3guMosZ) Further company coverage:

BRIEF-Haemonetics Announces Sale Of U.S. Blood Donor Management Software Solution Assets To The GPI Group

* HAEMONETICS ANNOUNCES SALE OF U.S. BLOOD DONOR MANAGEMENT SOFTWARE SOLUTION ASSETS TO THE GPI GROUP

BRIEF-GPI SpA To Acquire Haemonetics’ U.S. Blood Donor Software Assets

* GPI S.P.A. - BLOOD MANAGEMENT, GPI TO ACQUIRE HAEMONETICS’ U.S. BLOOD DONOR SOFTWARE ASSETS

BRIEF-Haemonetics Reports Q4 Adjusted Earnings Per Share $0.69

* Q4 EARNINGS PER SHARE VIEW $0.73, REVENUE VIEW $246.5 MILLION -- REFINITIV IBES DATA

BRIEF-Haemonetics Acquires Enicor GmbH To Expand Advanced Viscoelastic Testing Portfolio

* HAEMONETICS ACQUIRES ENICOR GMBH TO EXPAND ADVANCED VISCOELASTIC TESTING PORTFOLIO

BRIEF-Haemonetics Appoints Anila Lingamneni Executive Vice President, Chief Technology Officer

* HAEMONETICS APPOINTS ANILA LINGAMNENI EXECUTIVE VICE PRESIDENT, CHIEF TECHNOLOGY OFFICER Source text for Eikon: Further company coverage:

BRIEF-Haemonetics Reports Qtrly Earnings Per Share Of $0.22

* SEES FISCAL 2019 TOTAL REVENUE GROWTH 3 PERCENT TO 5 PERCENT

BRIEF-Haemonetics Announces Regulatory Clearances

* HAEMONETICS ANNOUNCES REGULATORY CLEARANCES OF NEXSYS PCS™ ENHANCED SOFTWARE WITH YES™ TECHNOLOGY Source text for Eikon: Further company coverage:

BRIEF-Haemonetics Corp Qtrly Revenue $234.0 Million

* QTRLY ADJUSTED EARNINGS PER SHARE $0.62; QTRLY LOSS PER SHARE $0.12

BRIEF-Haemonetics appoints David Wilson plasma business unit president

* Haemonetics appoints David Wilson plasma business unit president Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up